<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Lâ€‘Citrulline for AFib â€“ NO Pathway, Evidence, Dosage</title>
  <meta name="description" content="Lâ€‘citrulline and atrial fibrillation: nitricâ€‘oxide pathway, endothelial function, evidence, dosage, safety, and research links.">
  <link rel="canonical" href="https://atrial-fibrillation.org/citrulline.html">
  <meta property="og:title" content="Lâ€‘Citrulline for AFib â€“ NO Pathway, Evidence, Dosage">
  <meta property="og:description" content="Overview of Lâ€‘citrulline in AFib: NO bioavailability, vascular function, human associations and research links.">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://atrial-fibrillation.org/citrulline.html">
  <meta property="og:image" content="https://atrial-fibrillation.org/logo.svg">
  <link rel="icon" href="favicon.svg" type="image/svg+xml">
  <link rel="alternate icon" href="favicon.svg">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="styles.min.css?v=3">
</head>
<body>
  <header class="header">
    <nav class="nav">
      <div class="nav-container">
        <div class="nav-logo">
          <a href="index.html#home" class="nav-link">
            <img src="logo.svg" alt="Atrial Fibrillation Logo" class="logo" onerror="this.style.display='none'; this.nextElementSibling.style.display='block';">
            <div class="text-logo" style="display: none;">
              <span style="color: #2563eb; font-weight: bold; font-size: 18px;">ðŸ’“ Atrial Fibrillation</span>
            </div>
          </a>
        </div>
        <ul class="nav-menu">
          <li><a href="index.html#home" class="nav-link">Home</a></li>
          <li><a href="index.html#about" class="nav-link">What is AFib?</a></li>
          <li><a href="treatments.html" class="nav-link">Treatments</a></li>
          <li><a href="index.html#supplements" class="nav-link">Supplements</a></li>
          <li><a href="index.html#research" class="nav-link">Research</a></li>
          <li><a href="index.html#contact" class="nav-link">Contact</a></li>
        </ul>
      </div>
    </nav>
  </header>

  <main style="margin-top:80px;">
    <section class="container" style="padding-top:2rem; padding-bottom:2rem;">
      <div class="section-header">
        <h1>Lâ€‘Citrulline and Atrial Fibrillation</h1>
        <p>NO pathway support, evidence and practical considerations</p>
      </div>

      <article class="about-card" style="text-align:left;">
        <h2>Overview</h2>
        <p>Lâ€‘citrulline is a nonâ€‘essential amino acid that converts to Lâ€‘arginine, thereby increasing nitricâ€‘oxide (NO) bioavailability. In cardiovascular health, NO promotes vasodilation, improves endothelial function and may reduce vascular stiffnessâ€”mechanisms indirectly relevant to atrial fibrillation (AFib). Although direct randomized AF outcome trials for citrulline are limited, supporting evidence from vascular and perioperative literature plus human metabolomics suggests a plausible role as part of a comprehensive strategy alongside lifestyle and medical care.</p>

        <h2>How Citrulline Might Help in AFib</h2>
        <h3>1) Increasing NO bioavailability</h3>
        <p>Citrulline efficiently raises plasma arginine more consistently than oral arginine due to firstâ€‘pass metabolism differences. Greater NO availability can enhance endothelial function and microvascular flow. Better vascular health may lower triggers such as bloodâ€‘pressure spikes and improve overall cardiac workload.</p>
        <h3>2) Endothelial function and stiffness</h3>
        <p>Human supplementation studies outside AF consistently show improvements in flowâ€‘mediated dilation and surrogate markers of arterial stiffness after citrulline. While not AFâ€‘specific, these endpoints relate to cardiovascular risk and may influence the substrate in which AF arises or persists.</p>
        <h3>3) Perioperative/NO donor context</h3>
        <p>Randomized trials with NO donors (e.g., sodium nitroprusside) reduced postâ€‘operative AF after CABG. Citrulline is not a NO donor, but by enhancing NO pathways, it supports a mechanistic line consistent with these outcomes. This should be viewed as indirect evidence.</p>

        <h2>Evidence Summary</h2>
        <ul>
          <li><strong>NO donors and postâ€‘op AF:</strong> In CABG trials, AF incidence and duration were reduced under NO donor therapy (see <a href="index.html#research">Research</a>).</li>
          <li><strong>Human metabolomics:</strong> Plasma citrulline increased after successful catheter ablation, correlating with restored sinus rhythm (association, not causation).</li>
          <li><strong>Systematic reviews:</strong> Oral citrulline increases arginine and NO bioavailability and improves vascular function, though AFâ€‘specific outcome trials are scarce.</li>
        </ul>
        <p>For full citations and notes, visit the siteâ€™s <a href="index.html#research">Research section</a>.</p>

        <h2>Suggested Dosage (Informational)</h2>
        <p>Common supplemental ranges are <strong>3â€“6 g/day</strong>, often split into 2â€“3 doses to improve tolerance. Individuals may start lower and titrate. Those on antihypertensives or PDEâ€‘5 inhibitors should consult their clinician due to potential additive vasodilation.</p>
        <ul>
          <li><strong>Form:</strong> Lâ€‘citrulline powder or tablets; citrulline malate is also common in sports nutrition (note the malate component).</li>
          <li><strong>Timing:</strong> Split across the day; for exercise, a preâ€‘activity dose is sometimes used in performance literature.</li>
          <li><strong>Stacking:</strong> Can be combined with lifestyle measures targeting blood pressure, sleep and stress (see <a href="index.html#triggers">Triggers</a>).</li>
        </ul>

        <h2>Safety and Interactions</h2>
        <p>Citrulline is generally well tolerated. Potential issues include GI discomfort at higher doses and additive effects with bloodâ€‘pressure lowering agents or PDEâ€‘5 inhibitors. Patients with complex medical histories, kidney disease or pregnancy should seek personalized medical advice.</p>

        <h2>Practical Tips</h2>
        <ul>
          <li>Use citrulline as part of a broader AFib plan: address <a href="index.html#triggers">triggers</a>, optimize sleep, moderate alcohol and maintain hydration.</li>
          <li>Monitor blood pressure and symptoms; discuss trends with your clinician.</li>
          <li>Reassess need and dose after rhythm procedures (e.g., ablation) or medication changes.</li>
        </ul>

        <div class="disclaimer" style="margin-top:1.5rem;">
          <p><strong>Medical disclaimer:</strong> This page is informational and not medical advice. AFâ€‘specific outcome evidence for citrulline remains limited; always consult your physician.</p>
        </div>

        <p style="margin-top:1rem;">Compare with <a href="taurine.html">taurine</a> or return to the <a href="index.html#research">Research</a> overview.</p>
      </article>
    </section>
  </main>

  <footer class="footer">
    <div class="container">
      <div class="footer-bottom">
        <p>&copy; atrial-fibrillation.org. All rights reserved.</p>
      </div>
    </div>
  </footer>
  <script src="script.min.js?v=3"></script>
</body>
</html>
